Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash papular23.03.13.017---
Rash pruritic23.03.13.030---
Rash vesicular23.03.13.009---
Rectal haemorrhage07.12.03.001; 24.07.02.0180.000918%
Renal cancer16.08.02.001; 20.01.04.0020.003380%-
Renal failure20.01.03.0050.002574%-
Renal haemorrhage12.01.05.004; 20.01.02.013; 24.07.07.0020.000224%
Renal infarct20.01.07.008; 24.01.11.0040.000112%-
Respiratory failure14.01.04.003; 22.02.06.0020.001567%
Restrictive cardiomyopathy02.04.01.005--
Retching07.01.07.0020.000604%-
Retinal detachment06.09.03.003; 12.01.04.0040.000448%
Retinal disorder06.08.03.0050.000246%-
Retinal tear06.09.03.010; 12.01.04.0140.000448%
Retinal vein occlusion06.10.01.010; 24.01.07.0060.000112%-
Retroperitoneal haemorrhage07.07.02.002; 12.01.17.018; 24.07.01.017--
Rhinorrhoea22.12.03.0210.001589%
Sarcoma15.09.03.002; 16.33.01.0020.000560%-
Sarcoma uterus16.33.01.001; 21.07.02.0050.000168%-
Sciatica15.10.01.001; 17.10.03.0010.000112%-
Second primary malignancy16.16.01.0140.001063%
Shock24.06.02.002---
Sinus bradycardia02.03.03.009--
Sjogren's syndrome06.08.02.011; 07.06.01.010; 10.04.04.009; 15.06.01.0150.000112%-
Skin depigmentation23.05.02.0020.001780%-
Skin discolouration23.03.03.0050.007275%-
Skin disorder23.03.03.0070.000795%-
Skin exfoliation23.03.07.0030.002518%-
Skin fissures23.03.03.0080.000492%-
Skin hyperpigmentation23.05.01.0030.000571%
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 21 Pages